Tolerance and Effect on Intraocular Pressure After Administration of SYL040012

Inclusion criteria

• Healthy volunteers, any gender
• 18 to 45 years of age,
• Subjects must provide signed informed consent prior to participation in any study-related procedures
• Body Mass Index between 19,5 and 29 kg/m2
• IOP </= 21 mmHg in both eyes
• Have a BCVA (Best corrected visual acuity) of >/= 0.8 (20/25) (Snellen scale), or </= 0.1 (LogMar units)in both eyes
• Normal Fluorescein Clearance Test in both eyes
• Normal funduscopy in both eyes

Exclusion criteria

• Pregnant or breastfeeding females or those with a positive pregnancy test. Females of childbearing potential who will not use a medically acceptable contraceptive method from selection and during the hole study.
• Current relevant disease, including respiratory disease, cardiovascular, endocrine, neurological, haematological, renal, neoplastic, hepatopathy, gastrointestinal distress, hypertension, or infectious acute processes
• Previous chronic processes or with rebound characteristics that could interfere with study according to the investigator's judgment.
• Volunteers who have received pharmacological treatment, including medicinal plants, during the four weeks previous to beginning the study.
• Having used anti-cholinergics, betablockers and corticoids sporadically in the last 30 days whichever the route of administration, or any med by ocular or nasal administration route.
• Case history of hypersensitivity to meds or any other allergic process
• Visual alterations: Previous eye surgery, glaucoma, uveitis or ocular surface pathology (dry eye, blepharitis).
• Volunteers with visual alteration with more than 3 dioptres in either eye
• Use of contact lenses
• Volunteer who has participated in a clinical trial during the past four months before study entry.
• Blood or derivate transfusion during the six previous months to study entry
• Case history of drug or alcohol abuse or dependence.
• Positive result in test drug abuse during selection period
• Positive serology results to hepatitis B virus (HbsAg), virus C or HIV
• Analytic alterations medically relevant, at investigator's judgement.